Wed, Dec 24, 2014, 7:29 PM EST - U.S. Markets closed early today

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • zake1 zake1 Sep 3, 2013 10:42 PM Flag

    It won't be long now

    Resource links provided by NLM:


    MedlinePlus related topics: Antibiotics Mycobacterial Infections

    Drug Information available for: Amikacin sulfate
    U.S. FDA Resources


    Further study details as provided by Insmed:


    Primary Outcome Measures: •Change in semi-quantitative mycobacterial culture results from baseline to end of treatment [ Time Frame: 84 days ] [ Designated as safety issue: Yes ]


    Secondary Outcome Measures: •Proportion of subjects with culture conversion to negative [ Time Frame: 84 days ] [ Designated as safety issue: Yes ]

    •Time to "rescue" anti-mycobacterial drugs [ Time Frame: 84 days ] [ Designated as safety issue: Yes ]

    •Change from baseline in 6-minute walk distance and oxygen saturation [ Time Frame: 84 days ] [ Designated as safety issue: Yes ]

    •Change from baseline in Patient Reported Outcomes [ Time Frame: 84 days ] [ Designated as safety issue: Yes ]

    •Evaluation of safety and tolerability [ Time Frame: For entire study duration ] [ Designated as safety issue: Yes ]

    Estimated Enrollment: 100
    Study Start Date: May 2012
    Estimated Study Completion Date: August 2013
    Estimated Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This shows and end date in August.

    • Now this is the proper use of public message boards.

    • Detailed Description:

      This is a randomized, double-blind study evaluating the efficacy and safety of Arikace® administration compared to placebo for 84 days in subjects with recalcitrant non-tuberculous mycobacterial lung disease on a stable multi-drug regimen. Subjects will be randomized 1:1 to either 560 mg Arikace® or placebo administered once a day via a PARI Investigational eFlow® nebulizer. Subjects will visit the clinic about every 28 days for efficacy, safety and tolerability evaluations. At the conclusion of the double-blind portion of the study, subjects who have consented to additional treatment, will participate in an 84 day open label phase of once daily Arikace® treatment. A follow-up safety visit will occur 28 days after the conclusion of the open label treatment phase. Throughout the entire study, sputum, blood and urine specimens will be collected to assess drug concentrations in subjects who consent for Pharmacokinetic (PK) evaluation.

      Eligibility

      Ages Eligible for Study: 18 Years to 85 Years
      Genders Eligible for Study: Both
      Accepts Healthy Volunteers: No

      Criteria

      Key Inclusion Criteria:
      1.Diagnosis of pulmonary nontuberculous mycobacterial lung disease in accordance with the 2007 ATS/IDSA criteria with evidence of nodular bronchiectasis and/or cavitary disease by chest computed tomography (CT).
      2.History of chronic infection with either Mycobacterium avium complex or Mycobacterium abscessus or mixed infection with both species (defined as at least 2 documented positive cultures in the prior 2 years, of which at least one was obtained in the 6 months prior to screening).
      3.Positive sputum culture obtained at screening visit with either Mycobacterium avium complex or Mycobacterium abscessus or mixed infection with one dominant species.
      4.Receiving ATS/IDSA guidelines-based treatment regimen defined as: adherent to a multi-drug regimen for at least 6 months prior to screening with persistently positive mycobacterial cultures.
      5.Ability to produce at least 3 mL of sputum or be willing to undergo an induction that produces at least 3 mL of sputum for clinical evaluation.
      6.Female of childbearing potential agrees to practice an acceptable method of birth control (e.g., abstinence, hormonal or barrier methods, partner sterilization, or IUD).

      Key Exclusion Criteria:
      1.Forced Expiratory Volume in 1 second (FEV1) 450 msec for males or QTc 470 msec for females.
      3.Subjects with hemoptysis of ≥60 mL in a 24 hour period within 4 weeks prior to screening.
      4.Active pulmonary malignancy (primary or metastatic) or any malignancy requiring chemotherapy or radiation therapy within one year prior to screening or anticipated during the study period.
      5.Active allergic bronchopulmonary mycosis or any other condition requiring systemic steroids at a dose ≥ equivalent of 10 mg/day of prednisone within 3 months prior to screening or anticipated during the study period.
      6.Pulmonary tuberculosis requiring treatment or treated within 2 years prior to screening.
      7.History of lung transplantation.
      8.Hypersensitivity to aminoglycosides.
      9.Any change in chronic NTM multi-drug regimen within 28 days prior to Study Day 1.
      10.Evidence of biliary cirrhosis with portal hypertension.
      11.History of daily, continuous oxygen supplementation.
      12.Smoking tobacco or any substance within 6 months prior to screening or anticipated inability to refrain from smoking throughout the study

 
INSM
15.29+0.15(+0.99%)Dec 24 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.